Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6–7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8–10

Doo Yong Chung 1,2, Jong Soo Lee 2, Hyeok Jun Goh 2, Dong Hoon Koh 2, Min Seok Kim 2, Won Sik Jang 2 and Young Deuk Choi 2,*

1 Department of Urology, Inha University School of Medicine, 366 Seohae-daero, Jung-gu, Incheon 22332, Korea; wjdendyd@gmail.com
2 Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea; JS1129@yuhs.ac (J.S.L.); JOON8301@yuhs.ac (H.J.G.); DHKOH@yuhs.ac (D.H.K.); KMSVVVV4928@yuhs.ac (M.S.K.); SINDAKJANG@yuhs.ac (W.S.J.)

* Correspondence: YOUNGD74@yuhs.ac; Tel.: +82-22-228-2317; Fax: +82-23-122-538

Received: 6 February 2019; Accepted: 25 March 2019; Published: 30 March 2019

Abstract: Gleason score (GS) 8–10 is associated with adverse outcomes in prostate cancer (PCa). However, biopsy GS (bGS) may be upgraded or downgraded post-radical prostatectomy (RP). We aimed to investigate predictive factors and oncologic outcomes of downgrade to pathologic GS (pGS) 6–7 after RP in PCa patients with bGSs 8–10. We retrospectively reviewed clinical data of patients with bGS ≥ 8 undergoing RP. pGS downgrade was defined as a pGS ≤ 7 from bGS ≥ 8 post-RP. Univariate and multivariate cox regression analysis, logistic regression analysis, and Kaplan–Meier curves were used to analyze pGS downgrade and biochemical recurrence (BCR). Of 860 patients, 623 and 237 had bGS 8 and bGS ≥ 9, respectively. Post-RP, 332 patients were downgraded to pGS ≤ 7; of these, 284 and 48 had bGS 8 and bGS ≥ 9, respectively. Prostate-specific antigen (PSA) levels, clinical stage, and adverse pathologic features such as extracapsular extension, seminal vesicle invasion, and positive surgical margin were significantly different between patients with pGS ≤ 7 and pGS ≥ 8. Furthermore, bGS 8 (odds ratio (OR): 0.349, \( p < 0.001 \)), PSA level < 10 ng/mL (OR: 0.634, \( p = 0.004 \)), and ≤cT3a (OR: 0.400, \( p < 0.001 \)) were identified as significant predictors of pGS downgrade. pGS downgrade was a significant positive predictor of BCR following RP in patients with high bGS (vs. pGS 8, hazard ratio (HR): 1.699, \( p < 0.001 \); vs. pGS ≥ 9, HR: 1.765, \( p < 0.001 \)). In addition, the 5-year BCR-free survival rate in patients with pGS downgrade significantly differed from that in patients with bGS 8 and ≥ 9 (52.9% vs. 40.7%, \( p < 0.001 \)). Among patients with bGS ≥ 8, those with bGS 8, PSA level < 10 ng/mL, and ≤cT3a may achieve pGS downgrade after RP. These patients may have fewer adverse pathologic features and show a favorable prognosis; thus we suggest that active treatment is needed in these patients. In addition, patients with high-grade bGS should be managed aggressively, even if they show pGS downgrade.

Keywords: prostatic neoplasms; magnetic resonance imaging; gleason score

1. Introduction

Prostate cancer (PCa) is the most common type of newly diagnosed malignancy in men [1], and it accounts for nearly 30% of all diagnosed male cancers [2]. Prostate-specific antigen (PSA) measurements are widely used for PCa screening [3], and patients with elevated PSA levels undergo
prostate biopsy for PCa diagnosis [4]. The Gleason score (GS) is the most commonly used grading system for PCa. Gleason score at prostate biopsy (bGS) is one of the important parameters in the evaluation, risk stratification, and selection of treatment modality in PCa patients [5,6]. Gleason score was first introduced in 1974 by Donald Gleason and the Veterans Administration Cooperative Urologic Research Group [7]. GS is continuously updated, and it was first revised in 2005 in the International Society of Urological Pathology (ISUP) conference [8]. In the 2014 ISUP meeting, GS was further revised, and a new 5-step Gleason grading system was introduced [9]. Despite these revisions, bGS ≥8 is still considered as high risk [10].

Biopsy and radical prostatectomy (RP) specimens can be discordant due to sampling errors and the multifocal nature of PCa [11]. Several studies have already reported GS discrepancies between biopsy and RP specimens [12,13]. A GS downgrade may also occur in patients with bGS ≥8 [14,15]. However, few studies have predicted the discordance in GS between biopsy and RP specimens in patients with bGS ≥8. We believe that predicting pathological downgrade (pGS ≤7) in patients with high-grade prostate cancer may be beneficial in terms of oncologic outcomes and provide a reliable parameter for defining the appropriate surgical treatment strategy. Therefore, this study aimed to investigate prognostic factors of GS downgrade from biopsy to RP and to investigate oncologic outcomes after RP in patients with bGS ≥8.

2. Materials and Methods

2.1. Patients and Study Design

We retrospectively retrieved the clinical and pathological data of 5438 PCa patients who underwent RP at our institution between January 2005 and December 2016. Patients who had undergone androgen deprivation therapy or external beam radiation therapy before RP and those with incomplete pathological or follow-up data were excluded. All patients were diagnosed with PCa via transrectal ultrasound (TRUS)-guided 12-core systematic needle biopsy.

The clinical characteristics of these patients including age, body mass index (BMI), preoperative PSA levels, prostate volume measured via TRUS, clinical stage on multiparametric magnetic resonance imaging (mpMRI), GS following prostate biopsy, and pathologic characteristics of RP specimens were obtained through a review of medical records. The mpMRI images included standardized criteria for Likert scoring of multiparametric sequences using a 3.0-T MRI system (Intera Achieva 3.0-T, Phillips Medical System, Best, The Netherlands) [16]. All pathologic diagnoses were performed by expert pathologists. Biopsy specimens obtained from other hospitals were reviewed by our pathologists. The pathologists also reviewed the missing data in pathological reports of patients included in our study and confirmed that there was no problem. The final identification was performed by the most skilled pathologist to reduce possible errors between pathologists. We assigned GS according to the 2005 ISUP Modified Gleason System [8]. Gleason score at prostate biopsy was based on the core with the highest GS. In case of multifocal disease, GS of the RP specimen was assigned based on the nodule with the highest GS. Tertiary Gleason 5 patterns were assigned if the tertiary component comprised <5% of the entire tumor [17]. Gleason score downgrade was defined as a downgrade to GS ≤7 in the RP specimen from a bGS ≥8, which is classified as high-grade.

Finally, the tumor-node-metastasis (TNM) stage was determined according to the 8th edition of the American Joint Committee on Cancer TNM staging system.

2.2. Follow-Up

Follow-up postoperative PSA test was performed monthly for the first 6 months, every 3 months until the second year, and every 6 months thereafter. Biochemical recurrence (BCR) was defined as any two consecutive increases in serum PSA ≥0.2 ng/mL following RP. Biochemical recurrence-free survival was defined as the time from RP to BCR [18]. The follow-up period was calculated from the time of RP to the date of the last known contact with the patient.
2.3. Statistical Analysis

Univariate and multivariate Cox proportional hazards regression analyses were performed to assess the association between baseline parameters and BCR-free survival. In addition, univariate and multivariate logistic regression were performed to identify significant factors of pathologic downgrade. The Kaplan–Meier method with log-rank tests were performed to estimate and compare oncologic outcomes according to variations in GS from RP.

Significant variables from univariate analysis were included in multivariate analysis. All statistical analyses were performed using SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA), and \( p < 0.05 \) was considered statistically significant.

2.4. Ethics Approval and Informed Consent

The current research was approved by the Severance hospital institutional review board (approval number 4-2018-1012). Informed consent from the participants was waived by the institutional review board as the current study satisfied all of the following requirements for the waiver of informed consent: the research involved no more than minimal risk to the participants (retrospective data analysis of previously collected medical records).

3. Results

3.1. Patient and Disease Characteristics

Of the 5438 patients identified, 1126 had bGS \( \geq 8 \). After excluding 266 patients who received neoadjuvant therapy, 860 patients were finally included in the analysis. In total, 623 (72.4\%) and 237 (27.6\%) patients had bGS 8 and bGS \( \geq 9 \), respectively. In the 860 specimens collected following RP, the GS were 6, 7, 8, and \( \geq 9 \) in 19 (2.2\%), 313 (36.4\%), 219 (25.5\%), and 309 (35.9\%) specimens, respectively. Among 313 patients in GS 7, 130 (15.1\%) had GS (3 + 4) and 183 (21.2\%) had GS (4 + 3). Therefore, 332 (38.6\%) patients with pGS \( \leq 7 \) were followed after RP for pGS downgrade; the remaining 528 (61.4\%) patients had pGS \( \geq 8 \). Median follow-up period after RP was 51 months (interquartile range, 26–78 months). In addition, patients with tertiary G5 patterns in the total RP specimen were observed 15 in GS7 (3 + 4), 23 in GS7 (4 + 3) and 15 in GS8 (4 + 4).

When dividing the two groups (pGS \( \leq 7 \) vs. pGS > 8) based on pathologic GS, there were significant differences in preoperative PSA, PSA density, clinical stage, and bGS between the two groups. Meanwhile, age, BMI, prostate volume, and follow-up duration did not differ significantly.

After RP, there were statistically significant differences in the pathological features (extracapsular extension (ECE), seminal vesicle invasion (SVI), positive surgical margin (PSM), lymphovascular invasion, and perineural invasion) between the two groups (Table 1).

| Variable | Total N = 860 | No Downgrade N = 528 (61.4\%) | Downgrade N = 332 (38.6\%) | \( P \) value |
|----------|--------------|-------------------------------|-----------------------------|-----------|
| Age, year | Median IQR  | Median IQR  | Median IQR  | 0.578     |
| BMI, kg/m\(^2\) | 24.09 22.38–25.97 | 24.05 22.32–25.90 | 24.22 22.50–26.00 | 0.608     |
| PSA level, ng/mL | 10.59 6.58–19.39 | 12.03 7.09–22.72 | 8.60 5.99–14.74 | <0.001    |
| PSA group, ng/mL | N % | N % | N % | <0.001    |
| \( \geq 10 \) | 415 48.3 | 292 55.3 | 123 37.0 | 0.001    |
| PSA density, ng/mL\(^2\) | 0.33 0.20–0.62 | 0.38 0.22–0.75 | 0.28 0.18–0.50 | <0.001    |
| Prostate volume, mL | 32.0 26.0–40.5 | 32.6 26.0–40.9 | 31.1 25.8–40.0 | 0.367     |
| Clinical stage according to MRI | | | | <0.001    |
| cT2 | 402 46.7 | 213 40.3 | 35 56.9 | 0.003     |
| cT3a | 292 34.0 | 176 33.3 | 116 34.9 | 0.009     |
| cT3b | 166 19.3 | 139 26.3 | 27 8.1 | 0.001     |
| Gleason score according to Biopsy 8 | | | | <0.001    |
| \( \geq 9 \) | 237 27.6 | 189 35.8 | 48 14.5 | 0.137     |
| FU duration after RP, months | 51 26–78 | 44 25–71 | 9 32–83 | 0.317     |

Table 1. Baseline patient characteristics.
Table 1. Cont.

| Variable | Total | No_Downgrade | Downgrade |
|----------|-------|--------------|-----------|
|          | N = 860 | N = 528 (61.4%) | N = 332 (38.6%) |
|          | Median | IQR | Median | IQR | Median | IQR |

Pathologic Features after Radical Prostatectomy

| Variable | Total | No_Downgrade | Downgrade |
|----------|-------|--------------|-----------|
|          | N = 860 | N = 528 (61.4%) | N = 332 (38.6%) |
|          | Median | IQR | Median | IQR | Median | IQR |

| Pathologic T Stage according to Radical Prostatectomy | Total | No_Downgrade | Downgrade |
|------------------------------------------------------|-------|--------------|-----------|
|                                                      | N = 860 | N = 528 (61.4%) | N = 332 (38.6%) |
|                                                      | Median | IQR | Median | IQR | Median | IQR |

3.2. Preoperative Factors Related to Pathologic Gleason Score (GS) Downgrade (pGS ≤ 7)

In this study, we used univariate and multivariate logistic regression analyses to identify preoperative predictors of pathologic GS downgrade. Preoperative PSA ≥ 10 ng/mL (odds ratio (OR): 0.606, 95% confidence interval (CI): 0.438–0.840, \( p = 0.003 \)), bGS ≥ 9 (OR: 0.303, 95% CI: 0.213–0.432, \( p < 0.001 \)), and ≥ cT3b on mpMRI (OR: 0.284, 95% CI: 0.176–0.458, \( p < 0.001 \)) were found to be independent predictors of pathologic GS downgrade at RP in both univariate and multivariate models (Table 2). Also, in relate of pathologic downgrade, the area under the curves of the receiver operating characteristic curve was 0.614 (95% CI: 0.575–0.653) in patients with bGS 8, PSA level < 10 ng/mL, and ≤ cT3a.

Table 2. Univariate and multivariate analyses of factors associated with pathologic Gleason score downgrade in patients with biopsy Gleason scores 8–10.

| Variable | Univariate | OR (95% CI) | \( p \) Value | Multivariate | OR (95% CI) | \( p \) Value |
|----------|------------|-------------|---------------|-------------|-------------|---------------|
| Age, year | 0.995 (0.975–1.015) | 0.592 | | | | |
| BMI, kg/m² | 1.013 (0.964–1.064) | 0.607 | | | | |
| Prostate volume, mL | 0.996 (0.986–1.005) | 0.367 | | | | |
| PSA level, ng/mL | | | | | | |
| <10 | 1 (Ref) | | | | | |
| ≥10 | 0.476 (0.359–0.630) | <0.001 | | | | |
| PSA density | 0.679 (0.540–0.854) | 0.001 | | | | |
| Gleason score | | | | | | |
| 8 | 1 (Ref) | | | | | |
| ≥9 | 0.303 (0.213–0.432) | <0.001 | | | | |
| Clinical stage according to MRI | | | | | | |
| cT2 | 1 (Ref) | | | | | |
| cT3a | 0.743 (0.547–1.008) | 0.056 | | | | |
| ≥cT3b | 0.219 (0.139–0.346) | <0.001 | | | | |

OR, odds ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen; MRI, magnetic resonance imaging.
3.3. Supplementary Analysis of 3-2 (646 Cases)

We analyzed the presence of low-grade PCa core in the biopsy specimens in patients with bGS ≥ 8. In total of 646 cases, we were able to analyze all 12 biopsy cores, including the highest GS. Among the positive biopsy cores, the patients containing Low GS (bGS < 8) was 356 cases of them. In our result, presence of low GS core in biopsy was statistically significant with pathologic downgrade. (OR 3.967, 95% CI: 2.698–5.833, p < 0.001). In addition, we analyzed according to the lowest GS in biopsy. The cases including bGS6 were OR 4.926, 95% CI: 3.119–7.779, p < 0.001. The cases including bGS7 (3 + 4) were OR 4.299, 95% CI: 2.566–7.204, p < 0.001. And the cases including bGS7 (4 + 3) were OR 2.259, 95% CI: 0.176–0.458, p = 0.006.

3.4. Oncologic Outcomes and Prognostic Factors

During the follow-up period, 502 cases (58.4%) of BCR were noted. Univariate and multivariate Cox regression analyses were performed with each clinical parameter for BCR. In these analyses, preoperative PSA (hazard ratio [HR]: 1.005, p = 0.003), PSA ≥10 ng/mL (HR: 1.53, p < 0.001), bGS ≥9 (HR: 1.233, p = 0.042), pGS (pGS ≤7 vs. pGS 8: HR: 1.699, p < 0.001 and vs. pGS ≥9: HR: 1.765, p < 0.001), SVI (HR: 1.820, p < 0.001), and PSM (HR: 1.819, p < 0.001) were all independent prognostic factors for BCR (Table 3).

Table 3. Univariate and multivariate analyses of factors associated with biochemical recurrence.

| Variable                           | Univariate                      |         | Multivariate                  |         |
|------------------------------------|---------------------------------|---------|------------------------------|---------|
|                                    | HR (95% CI)                     | p Value | HR (95% CI)                  | p Value |
| Age, year                          | 1.005 (0.992–1.018)             | 0.469   |                              |         |
| Body mass index, kg/m²              | 1.014 (0.982–1.046)             | 0.399   |                              |         |
| Prostate volume, ml                | 1.003 (0.997–1.008)             | 0.563   |                              |         |
| PSA, ng/mL <10                     | 1.006 (1.005–1.008)             | <0.001  | 1.005 (1.002–1.009)          | 0.003   |
| PSA, ng/mL ≥10                     | 2.341 (1.956–2.803)             | <0.001  | 1.539 (1.260–1.880)          | <0.001  |
| PSA density, ng/mL²                | 1.186 (1.127–1.249)             | <0.001  | 0.888 (0.780–1.011)          | 0.073   |
| Biopsy Gleason score (bGS)         | 1 (Ref)                         |         | 1 (Ref)                      |         |
| ≤8                                 | 1.784 (1.485–2.143)             | <0.001  | 1.233 (1.008–1.508)          | 0.042   |
| ≥9                                 |                                  |         |                              |         |
| Pathologic Gleason score (pGS)     | 1 (Ref)                         |         | 1 (Ref)                      |         |
| ≤7 (pGS_downgrade)                 | 1.735 (1.366–2.204)             | <0.001  | 1.699 (1.328–2.175)          | <0.001  |
| ≥9                                 | 2.810 (2.272–3.474)             | <0.001  | 1.765 (1.396–2.231)          | <0.001  |
| Pathologic T stage                 |                                  |         |                              |         |
| ≤T2                               | 1 (Ref)                         |         | 1 (Ref)                      |         |
| ≥T3                               | 5.044 (3.910–6.508)             | <0.001  | 1.409 (0.788–2.520)          | 0.247   |
| ECE                               | 2.641 (2.122–3.286)             | <0.001  | 1.016 (0.594–1.737)          | 0.955   |
| SVI                               | 3.139 (2.598–3.792)             | <0.001  | 1.820 (1.473–2.249)          | <0.001  |
| PSM                               | 2.775 (2.298–3.351)             | <0.001  | 1.819 (1.476–2.242)          | <0.001  |
| LVI                               | 2.069 (1.639–2.612)             | <0.001  | 1.260 (0.967–1.608)          | 0.063   |
| PNI                               | 2.013 (1.612–2.512)             | <0.001  | 1.244 (0.979–1.580)          | 0.074   |
| HGPIN                             |                                  |         |                              |         |
| No                                | 0.870 (0.728–1.040)             | 0.126   |                              |         |
| Yes                               | 1 (Ref)                         |         | 1 (Ref)                      |         |

HR, hazard ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen; ECE, extracapsular extension; SVI, seminal vesicle invasion; PSM, positive surgical margins; LVI, lymphovascular invasion; PNI, perineural invasion; HGPIN, high-grade prostatic intraepithelial neoplasia; BCR, biochemical recurrence.
Analysis according to bGS and pGS using Kaplan–Meier curves was also conducted. In the pGS downgrade group, the Kaplan–Meier curve showed significantly better BCR-free survival than that in the other group (log-rank test, \( p < 0.001 \)). The 5-year BCR-free survival rates was higher in the pGS downgrade group than that in the other group (50.9% vs. 23.8%). Also, patients with bGS 8, PSA < 10 ng/mL, and \( \leq cT3a \) showed significantly better 5-year BCR-free survival than the other patients (55.1% vs. 23.4%, \( p < 0.001 \); Figures 1 and 2).

**Figure 1.** Kaplan–Meier curves for biochemical recurrence (BCR)-free survival according to pathologic Gleason score downgrade.

**Figure 2.** Kaplan–Meier curves for biochemical recurrence (BCR)-free survival according to bGS 8, PSA < 10 ng/mL, and \( \leq cT3a \).
The patients were then divided into four groups as follows for further analysis: group 1 comprised patients with bGS 8 and pGS < 7; group 2, patients with bGS ≥ 9 and pGS < 7; group 3, patients with bGS ≥ 9 and pGS ≥ 8; and group 4, patients with bGS ≥ 9 and pGS ≥ 8. The 5-year BCR-free survival rates for groups 1, 2, 3, and 4 were 52.9%, 40.7%, 27.2%, and 16.9%, respectively. The hazard ratios of groups 2, 3, and 4 compared to group 1 were 2.109 (p = 0.146), 38.643 (p < 0.001), and 96.262 (p < 0.001), respectively. The BCR-free survival curves of the four groups are shown in Figure 3.

Figure 3. Kaplan–Meier curves for biochemical recurrence (BCR)-free survival according to bGS and pGS.

4. Discussion

Since the introduction of the Gleason Grading System [7], bGS 8 or higher has been consistently classified as high risk and as a predictor of poor oncologic outcome. Patients with bGS 8 are classified to have high-grade prostate cancer (poorly differentiated prostate cancer). Since the 2005 update in the Gleason grading system [8], the correlation between bGS and RP GS has improved [19–21]. Major changes in the Gleason system have also been made during the 2014 ISUP [9], and this further improves the association between bGS and pGS [22]. However, some cases of discordant bGS and pGS are still reported. Among patients with PCa, those with GS > 8, PSA > 20 ng/mL, or cT3a are considered to be high risk. Although RP is a treatment option in these patients, combined EBRTx and ADT are proposed as the first choice of treatment in the National Comprehensive Cancer Network (NCCN) guideline [10]. The European Association of Urology (EAU) guideline also recommends RP for selected patients [4], and both the EAU and NCCN guidelines recommend RP in select high-risk patients. Therefore, in this study, we investigated the favorable indicators for surgical treatment in patients with high-risk PCa.

pGS downgrade is a well-known favorable prognostic factor, and Donohue et al. [14] reported that patients with high bGS who have pGS downgrade have good prognosis. In their study, cT1c and bGS 8 were identified to be predictors of pGS downgrade, which is similar to our results. However, there were differences about the influence of PSA and clinical stage between the study of Donohue et al.
and our study. In our study, PSA was set as a criterion for easy patient and used a PSA value of 10 ng/mL as cut-off for low-risk malignancy based on the current standard [10]. Thus, PSA <10 ng/mL was evaluated as a predictor for downgrading in patients with high-grade PCa on biopsy findings. In addition, recent developments in mpMRI have improved the image evaluation techniques for ECE and SVI [23,24]. The clinical stage was evaluated using 3T MRI, which enabled us to distinguish between T3a and T3b. Thus, the probability of discordance (i.e., pathologic downgrade) in patients with T3b or higher was minimized. In addition, we found that bGS8, PSA < 10 ng/mL, and ≤cT3a were significantly correlated with BCR in patients with high bGS. These factors were also predictors of pathologic downgrade. The Kaplan–Meier curves of the patients with pathologic downgrade and those with bGS8, PSA < 10 ng/mL, and ≤cT3a were similar in this study.

Collectively, these results indicate that patients with high-grade PCa who have PSA < 10 ng/mL, bGS 8, and ≤cT3a may have favorable oncological outcomes via RP. This information would be valuable in providing an indication for surgical treatment in patients with high-grade PCa. In addition, we believe that bGS remains a crucial factor for determining the appropriate treatment and follow-up strategy for high-grade PCa.

The oncologic outcome has been reported to differ according to bGS among those with similar pGS [11,22]. In our study, we also found that BCR-free survival decreased as bGS increased among those with similar pGS. This suggests that although pGS downgrades may be observed in patients with high-grade PCa on biopsy, these patients require a more aggressive management after RP than those with low-grade PCa.

Our study has several limitations. First, this was a retrospective review of data from patients treated at a single institution. Thus, our results are subject to selection bias, limiting generalizability. Therefore, multi-center, prospective studies are needed. Second, mpMRI findings have been recently read based on the Prostate Imaging Reporting and Data System (PI-RADS) [25,26]. However, until 2009 we did not include diffusion-weighted imaging and the apparent-diffusion coefficient in the mpMRI protocol. Therefore, it was difficult to perform a complete PI-RADS scoring. Recently, PI-RADS scoring has been reported to be associated with GS [27,28], and this requires further analysis. Third, given the referral nature of our tertiary center, many men underwent biopsy at outside hospitals. While all biopsy slides were re-examined by a single experienced group of urological pathologists at our institute, biopsy data were lacking in some cases, such as the number of positive cores, percentage of cancer per core, and perineural invasion. In our study, the presence of low GS (bGS <8) core in positive biopsy cores and pathologic downgrade were statistically significant. Unfortunately, as mentioned earlier, biopsy data were lacking in some cases. Therefore, it was difficult to analysis the average cancer portion for all biopsy cores. We think that this analysis may be a good study to reduce the discordance of biopsy and final GS. However, as a tertiary center, we were able to accommodate many patients with high-grade PCa. Therefore, a large number of patients were included in this study. In addition, in the era of mpMRI, the index core via mpMRI fusion biopsy could be one factor that could reduce GS discrepancies between biopsy and RP specimen. Unfortunately, this was not included in our current study. Therefore, we believe that further research on this content is necessary.

Despite these limitations, our study is still valuable in that it demonstrates that bGS 8, PSA < 10 ng/mL, and <cT3b were independent predictors of downgrading GS after RP in patients with high-grade PCa. In addition, these factors were determined to be predictors of favorable oncological outcome in these patients. Our findings provide a guide for predicting disease prognosis and subsequent treatment planning in patients with high-grade PCa.

5. Conclusions

Among patients with high-risk PCa (i.e., those with bGS ≥ 8), those with bGS 8, PSA < 10 ng/mL, and without SVI on mpMRI may have pGS downgrade and favorable oncologic outcomes. These patients have fewer adverse pathologic features and can thus benefit from RP in terms of oncologic prognosis. Therefore, we suggest active treatment such as RP in these patients.
Author Contributions: Conceptualization, D.Y.C. and Y.D.C.; Data curation, J.S.L., H.J.G., D.H.K., M.S.K. and W.S.J.; Formal analysis, D.Y.C., J.S.L., H.J.G., D.H.K., M.S.K. and W.S.J.; Investigation, D.Y.C. and Y.D.C.; Methodology, D.Y.C.; Visualization, Y.D.C.; Writing: original draft, D.Y.C.; Writing: review & editing, D.Y.C. and Y.D.C.

Conflicts of Interest: The authors report no conflicts of interest in relation to this work.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30. [CrossRef] [PubMed]
2. Cooperberg, M.R.; Broering, J.M.; Kantoff, P.W.; Carroll, P.R. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J. Urol. 2007, 178, S14–S19. [CrossRef]
3. Cooperberg, M.R.; Lubeck, D.P.; Meng, M.V.; Mehta, S.S.; Carroll, P.R. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J. Clin. Oncol. 2004, 22, 2141–2149. [CrossRef]
4. Heidenreich, A.; Bastian, P.J.; Bellmunt, J.; Bolla, M.; Joniau, S.; van der Kwast, T.; Mason, M.; Matveev, V.; Wiegel, T.; Zattoni, F.; et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—Update 2013. Eur. Urol. 2014, 65, 124–137. [CrossRef]
5. Partin, A.W.; Kattan, M.W.; Subong, E.N.; Walsh, P.C.; Wojno, K.J.; Oesterling, J.E.; Scardino, P.T.; Pearson, J.D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997, 277, 1445–1451. [CrossRef] [PubMed]
6. D’Amico, A.V.; Whittington, R.; Malkowicz, S.B.; Schulz, D.; Blank, K.; Broderick, G.A.; Tomaszewski, J.E.; Renshaw, A.A.; Kaplan, I.; Beard, C.J.; et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280, 969–974. [CrossRef]
7. Gleason, D.F.; Mellinger, G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974, 111, 58–64. [CrossRef]
8. Epstein, J.I.; Allsbrook, W.C., Jr.; Amin, M.B.; Egevad, L.L.; Committee, I.G. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 2005, 29, 1228–1242. [CrossRef] [PubMed]
9. Epstein, J.I.; Egevad, L.; Amin, M.B.; Delahunt, B.; Srigley, J.R.; Humphrey, P.A.; Grading, C. The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 2016, 40, 244–252. [CrossRef] [PubMed]
10. Carroll, P.R.; Parsons, J.K.; Andriole, G.; Bahnson, R.R.; Castle, E.P.; Catalona, W.J.; D’Amico, A.T.; Davis, J.W.; Epstein, J.I.; Etzioni, R.B.; et al. NCCN guidelines insights: Prostate cancer early detection, version 2.2016. J. Natl. Compr. Cancer Netw. 2016, 14, 509–519. [CrossRef]
11. Muntener, M.; Epstein, J.I.; Hernandez, D.J.; Gonzalez, M.L.; Mangold, L.; Humphreys, E.; Walsh, P.C.; Partin, A.W.; Nielsen, M.E. Prognostic significance of gleason score discrepancies between needle biopsy and radical prostatectomy. Eur. Urol. 2008, 53, 767–776. [CrossRef]
12. Rajinikanth, A.; Manoharan, M.; Soloway, C.T.; Civantos, F.J.; Soloway, M.S. Trends in Gleason score: Concordance between biopsy and prostatectomy over 15 years. Urology 2008, 72, 177–182. [CrossRef]
13. Djavan, B.; Kadesky, K.; Klopukh, B.; Marberger, M.; Roehrborn, C.G. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict gleason scores of radical prostatectomy specimens. Eur. Urol. 1999, 35, 261–270. [CrossRef] [PubMed]
14. Donohue, J.F.; Bianco, F.J.; Kuroiwa, K.; Vickers, A.J.; Wheeler, T.M.; Scardino, P.T.; Reuter, V.A.; Eastham, J.A. Poorly differentiated prostate cancer treated with radical prostatectomy: Long-term outcome and incidence of pathological downgrading. J. Urol. 2006, 176, 991–995. [CrossRef]
15. Gansler, T.; Fedewa, S.; Qi, R.; Lin, C.C.; Jemal, A.; Moul, J.W. Most gleason 8 biopsies are downgraded at prostatectomy—Does 4 + 4 = 7? J. Urol. 2018, 199, 706–712. [CrossRef] [PubMed]
16. Chung, D.Y.; Koh, D.H.; Goh, H.J.; Kim, M.S.; Lee, J.S.; Jang, W.S.; Choi, Y.D. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI. BMC Cancer 2018, 18, 1057. [CrossRef]
17. Isbarn, H.; Ahyai, S.A.; Chun, F.K.; Budaus, L.; Schloimm, T.; Salomon, G.; Zacharias, M.; Erbersdobler, A.; Kollermann, J.; Sauter, G.; et al. Prevalence of a tertiary gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. *Eur. Urol.* 2009, 55, 394–401. [CrossRef]

18. Cronin, A.M.; Godoy, G.; Vickers, A.J. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. *J. Urol.* 2010, 183, 984–989. [CrossRef]

19. Billis, A.; Guimaraes, M.S.; Freitas, L.L.; Meirelles, L.; Magna, L.A.; Ferreira, U. The impact of the 2005 international society of urological pathology consensus conference on standard gleason grading of prostatic carcinoma in needle biopsies. *J. Urol.* 2008, 180, 548–552; discussion 552–553. [CrossRef]

20. Tsivian, M.; Sun, L.; Mouraviev, V.; Madden, J.F.; Mayes, J.M.; Moul, J.W.; Polascik, T.J. Changes in gleason score grading and their effect in predicting outcome after radical prostatectomy. *Urology* 2009, 74, 1090–1093. [CrossRef] [PubMed]

21. Uemura, H.; Hoshino, K.; Sasaki, T.; Miyoshi, Y.; Ishiguro, H.; Inayama, Y.; Kubota, Y. Usefulness of the 2005 international society of urologic pathology gleason grading system in prostate biopsy and radical prostatectomy specimens. *BJU Int.* 2009, 103, 1190–1194. [CrossRef] [PubMed]

22. Ham, W.S.; Chalfin, H.J.; Feng, Z.; Trock, B.J.; Epstein, J.I.; Cheung, C.; Humphreys, E.; Partin, A.W.; Han, M. The impact of downgrading from biopsy gleason 7 to prostatectomy gleason 6 on biochemical recurrence and prostate cancer specific mortality. *J. Urol.* 2017, 197, 1060–1067. [CrossRef] [PubMed]

23. Boesen, L.; Chabanova, E.; Logager, V.; Balslev, I.; Mikines, K.; Thomsen, H.S. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: A correlation with histopathology. *Eur. Radiol.* 2015, 25, 1776–1785. [CrossRef] [PubMed]

24. Feng, T.S.; Sharif-Afshar, A.R.; Wu, J.; Li, Q.L.; Luthringer, D.; Saouaf, R.; Kim, H.L. Multiparametric MRI improves accuracy of clinical nomograms for predicting extracapsular extension of prostate cancer. *Urology* 2015, 86, 332–337. [CrossRef]

25. Barentsz, J.O.; Richenberg, J.; Clements, R.; Choyke, P.; Verma, S.; Villeirs, G.; Rouviere, O.; Logager, V.; Futterer, J.J. ESUR prostate MR guidelines 2012. *Eur. Radiol.* 2012, 22, 746–757. [CrossRef]

26. Weinreb, J.C.; Barentsz, J.O.; Choyke, P.L.; Cornud, F.; Haider, M.A.; Macura, K.J.; Margolis, D.; Schnall, M.D.; Shtern, F.; Temppany, C.M.; et al. PI-RADS prostate imaging—Reporting and data system: 2015, version 2. *Eur. Urol.* 2016, 69, 16–40. [CrossRef]

27. Fainena, I.; Salmasi, A.; Mendhiratta, N.; Markovic, D.; Ahuja, P.; Hsu, W.; Elashoff, D.A.; Raman, S.S.; Reiter, R.E. PI-RADSV2 category on 3 tesla multiparametric prostate mri predicts oncologic outcomes in gleason 3+4 prostate cancer on biopsy. *J. Urol.* 2019, 201, 91–97. [CrossRef] [PubMed]

28. Krishna, S.; McNees, M.; Lim, C.; Lim, R.; Hakim, S.W.; Flood, T.A.; Schieda, N. Comparison of prostate imaging reporting and data system versions 1 and 2 for the detection of peripheral zone Gleason score 3 + 4 = 7 cancers. *AJR Am. J. Roentgenol.* 2017, 209, W365–W373. [CrossRef]